Recipharm, the contract development and manufacturing organisation (CDMO), has kick-started its campaign to introduce its customers to new processes for pharmaceutical serialisation
In February 2016, the CDMO announced plans to lead the market in preparing for new regulations to improve the traceability of drugs throughout the supply chain and invest over 40m euros into new systems and processes across around 75 production lines in Europe.
Just one year on, Recipharm has launched a fully operational line for serialisation at its facility in Fontaine, France and is engaging with customers to start the onboarding process.
From January 2018, the company will offer its drug serialisation service free of charge until it becomes a legal requirement in Europe in February 2019, allowing customers to overcome any challenges, determine their individual requirements and request any customisation before the legislation comes into force.
The CDMO’s company-wide serialisation project is being led by Staffan Widengren, director corporate projects at Recipharm.
He said: “Over the past couple of months several of our customers, ranging from mid- to large pharma, have visited our facility in Fontaine to view and trial our showcase line for pharmaceutical serialisation. The response we have received has been extremely positive, with customers feeling that our proactive approach to preparing for the changes will save them a lot of time and guarantee continuity of product supply when the new regulations take hold.”